Tag Archive : Drug

/ Drug

Nvidia  (NVDA) – Get Report said Monday it was partnering with GlaxoSmithKline  (GSK) – Get Report and its artificial intelligence group to use AI for developing new drugs and vaccines, while building a supercomputer to aid researchers in their work on the coronavirus and other challenges.

Shares of Nvidia, the Santa Clara, Calif.-based computer graphics chip company, were up 3.4% to $540.08, while American depositary receipts of GlaxoSmithKline rose 1.5% to $37.79. 

Located in London, GSK’s hub will use biomedical data, AI methods and advanced computing platforms to unlock genetic and clinical data, Nvidia said.

The GSK AI hub will be home to its U.K.-based AI team, including GSK AI Fellows, a new professional training program and now scientists from Nvidia.

“GSK and Nvidia together will help push the boundaries of what AI can do and put vast data sources to work to advance the discovery

Read More

VIENNA (Reuters) – India and South Africa want the World Trade Organization (WTO) to waive intellectual property rules to make it easier for developing countries to produce or import COVID-19 drugs, a letter https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/IP/C/W669.pdf&Open=True to the WTO shows.

In their letter dated Oct. 2 the two countries called on the global trade body to waive parts of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which governs patents, trademarks, copyright and other intellectual property rules globally.

“As new diagnostics, therapeutics and vaccines for COVID-19 are developed, there are significant concerns (over) how these will be made available promptly, in sufficient quantities and at (an) affordable price to meet global demand,” the letter posted on the Geneva-based WTO’s website says.

The two countries said that developing nations are disproportionately affected by the pandemic and that intellectual property rights, including patents, could be a barrier to the provision of affordable

Read More

DUBLIN, Oct. 2, 2020 /PRNewswire/ — The “Drug Modeling Software Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Product type; Application, and Geography” report has been added to ResearchAndMarkets.com’s offering.

According to this report the global drug modeling software biopharmaceutical market is expected to reach US$ 11,299.85 million by 2027 from US$ 6,205.22 million in 2019; it is estimated to grow at a CAGR of 8.1% from 2020 to 2027. The report highlights the trends prevalent in the global drug modeling software market, and the drivers and deterrents pertaining to its growth.

Based on product type, the drug modeling software market is segmented into database, software, and others. In terms of product type, the software segment held the highest share of the drug modeling software market in 2019 and is estimated to register the highest CAGR of 8.4% in the market during the forecast period. The

Read More

FDA’s Office of Pharmaceutical Quality adds new licenses of Simcyp Simulator

Certara, a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has again renewed and expanded its licenses of Certara’s biosimulation software, with more than 400 user licenses of Simcyp™ and Phoenix™ platforms. Eleven divisions and offices of the FDA use Certara’s software for internal research and to independently analyze, verify, and review regulatory submissions.

Certara’s Simcyp Simulator, an industry-leading platform for physiologically-based pharmacokinetic (PBPK) modeling and simulation, is used to determine first-in-human dose, design more efficient and effective clinical studies, and predict drug-drug interactions using virtual populations. The FDA’s Office of Clinical Pharmacology has renewed its licenses for the Simcyp Simulator, including Simcyp Pediatric and the Simcyp Cardiac Safety Simulator. Furthermore, the FDA’s Office of Pharmaceutical Quality recently ordered Simcyp user licenses, expanding the FDA’s use of the platform. The agency uses

Read More

Sunshine Coast Health Centre is a best-in-class alcohol, drug, PTSD and trauma treatment centre based in British Columbia, Canada. The Centre is proud to announce a visually stunning new website.


VANCOUVER, British Columbia – September 29, 2020 – (Newswire.com)

​Sunshine Coast Health Centre (https://www.sunshinecoasthealthcentre.ca/), top-rated drug rehabilitation and alcohol treatment program for men in British Columbia and throughout Canada, is proud to announce a new website. The new website combines stunning visuals with key information for persons and loved ones seeking to deal with trauma, PTSD, drug addiction, alcoholism and/or substance abuse issues.

“Websites such as ours need to not only convey information but convey the experience at a Centre such as ours,” explained Casey Jordan, Chief Marketing Officer. “We are so proud of our new website. The visuals convey the relaxed yet serious atmosphere, and the content conveys our treatment methodology. On the homepage, a key link goes to

Read More